Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZRX
|
|||
| Former ID |
DNC007074
|
|||
| Drug Name |
OXYRESVERATROL
|
|||
| Synonyms |
Oxyresveratrol; 29700-22-9; Tetrahydroxystilbene; (E)-4-(3,5-Dihydroxystyryl)benzene-1,3-diol; UNII-6V071CP5CR; trans-oxyresveratrol; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; OXYLRESVERATROL; 4721-07-7; 4-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol; CHEMBL43065; CHEBI:7870; 6V071CP5CR; 2,3',4,5'-Tetrahydroxystilbene; AK158555; 4-(3,5-Dihydroxystyryl)benzene-1,3-diol; J-501984; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,3-diol; 1,3-Benzenediol, 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]-; Puag-haad
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12O4
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1O)O)C=CC2=CC(=CC(=C2)O)O
|
|||
| InChI |
1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1+
|
|||
| InChIKey |
PDHAOJSHSJQANO-OWOJBTEDSA-N
|
|||
| CAS Number |
CAS 29700-22-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:7870
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosinase (TYR) | Target Info | Inhibitor | [1] |
| BioCyc | (S)-reticuline biosynthesis | |||
| Eumelanin biosynthesis | ||||
| L-dopachrome biosynthesis | ||||
| KEGG Pathway | Tyrosine metabolism | |||
| Riboflavin metabolism | ||||
| Metabolic pathways | ||||
| Melanogenesis | ||||
| Pathwhiz Pathway | Riboflavin Metabolism | |||
| Tyrosine Metabolism | ||||
| WikiPathways | Dopamine metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5650-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.